Table 4.

Sensitivity Analysis for Cost-effectiveness^a

Parameter	Range of Assumptions	Estimated Cost Saving per Patient Using Preemptive Therapy vs Prophylaxis, 2019 US Dollars
CMV PCR test costb	$45–$409	$6300–$11 000
Per diem hospitalizationc	$2500–$6000	$6700–$10 600
Per diem ICU utilizationc	$8000–$19 000	$7700–$12 600
Duration of hospitalizationd	5–21 d	$7600–$10 200
Duration of ICU stayd	0–7 d	$7000–$11 000
Percentage of CMV disease cases hospitalizede	58–93	$5500–$10 600
Percentage with viremia in preemptive therapy groupf	67–85	$8500–$10 100
Average cost for treatment of CMV disease, regardless of strategyg	$72 000–$106 000	$3600–$8300
Rate of CMV disease in prophylaxis groupf	.12–.30	−$1100h to $11 700
Rate of CMV disease in PET groupf	.02–.15	$1200–$9900

Abbreviations: CMV, cytomegalovirus; ICU, intensive care unit; PCR, polymerase chain reaction; PET, preemptive therapy.

^aData depict 1-way sensitivity analysis where 1 parameter/assumption at a time was changed across the range, while holding the other parameters constant at the estimate obtained in the clinical trial (base model). The base model takes into account the average cost of monitoring, cost of drugs given during prophylaxis, cost of drugs for preemptive therapy, antiviral treatment for CMV disease, disease rate for each strategy, and duration/cost of hospitalization and ICU utilization associated with disease in each strategy.

^bCost ranges include the highest and lowest cost in geographically diverse study sites as well as reference laboratories.

^cCost ranges include the highest and lowest costs in geographically diverse study sites.

^dDays are the interquartile range for duration of hospitalizations and ICU utilization for CMV disease in patients in this clinical trial.

^eConfidence intervals on proportion of disease subjects requiring hospitalization in the clinical trial.

^fRates previously described in the literature [22, 28–31].

^gInterquartile range for cost of treatment of disease, a composite of hospital utilization, drug costs, and diagnostic procedures averaged regardless of strategy.

^hProphylaxis was the dominant strategy when the rate of disease in that group was <12% with disease costs averaged across both groups.